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Abstract The ability of cells to synthesize and secrete proteins
is essential for numerous cellular functions. Therefore, when
mutations in one component of the secretory pathway result in
a tissue-speci¢c defect, a unique opportunity arises to examine
the molecular mechanisms at play. The recent ¢nding that a
defect in the protein sedlin, whose yeast counterpart is involved
in the ¢rst step of the secretory pathway, leads to a cartilage-
speci¢c disorder in humans raises numerous questions and inter-
esting possibilities for understanding both the pathobiology in-
volved and the role of membrane tra⁄c in normal cartilage
development.
 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Some ¢elds of research spawn natural alliances. Such is the
case, for example, with the ¢elds of apoptosis and cancer
research, inexorably linked through the study of both cell
cycle regulation and the protein p53. In other areas, such
cross-disciplinary studies between seemingly related ¢elds
never seem to rapidly materialize. This appears to be the
case with the ¢elds of membrane tra⁄c and cartilage develop-
ment. Indeed, it is well established that cartilage proteins,
including the abundant type II collagen, are synthesized intra-
cellularly and utilize the secretory pathway for traveling to
their ultimate destination. Fracture callus, an intermediate in
bone healing, requires, among other events, the deposition of
collagen in the form of cartilage. Given the large size of the
collagen macromolecules that are secreted, these processes
present a unique tra⁄cking problem for the cell. Chondro-
cytes, therefore, might serve as an interesting model system
in which to study the movement of such large molecules
through the pathway and to examine whether alternative
mechanisms, and perhaps other proteins, are employed. The
paucity of literature connecting these two areas is, therefore,
surprising.
That, however, may be changing. Recent work has demon-
strated a strong and undeniable connection between mem-
brane tra⁄c and cartilage development which should allow
for some interesting cell biological questions to now be ad-
dressed. This article will summarize that link, focusing mainly
on the ¢rst stage of the secretory pathway, and will present
some of the unresolved issues and lay out some of the chal-
lenges for further investigation.
2. Cartilage and ER^Golgi transport
Articular cartilage is composed of both collagenous and
non-collagenous proteins [1]. Of the collagen family, type II
collagen is the predominant form in cartilage [1,2]. Synthesis
of these proteins is initiated at the rough endoplasmic retic-
ulum (ER) where, upon translocation into the ER, the pro-
teins receive their initial carbohydrate moieties. In the case of
collagen, the protein receives proline modi¢cations and is as-
sembled into a triple helix bundle before leaving the ER as a
large macromolecule. Transport to the Golgi complex allows
for further modi¢cation of the sugar residue side chains ulti-
mately leading to the mature protein in a form ready for
secretion into the extracellular space. As some of the transport
vesicles carrying these components are relatively small (V50
nm in diameter), a mechanism to transport any components
greater than this size must be employed. This is particularly
an issue for many of the collagens (including type II collagen)
and some of the proteoglycan core proteins, whose lengths
range into the hundreds of nanometers [3]. The movement
of procollagen type I through the Golgi complex has been
studied kinetically and at the ultrastructural level [4] and it
was postulated that the protein travels through the Golgi by a
progressive maturation of the cisternal stacks (‘cisternal mat-
uration’ model). In another study, using an arti¢cially induced
protein aggregate to follow tra⁄c through the Golgi, Volchuk
et al. [5] described much larger vesicles than had been previ-
ously identi¢ed. Such so-called megavesicles appeared at the
edges of the Golgi cisternae and little of the marker aggregate
was detected in more internal regions of the stack. Similar
distensions of the Golgi were also visualized for the large
lipoprotein apolipoprotein E [6]. Given the small size of
ER-derived transport vesicles (also V50 nm in diameter), it
is not entirely clear how these large molecules transit from the
ER to the Golgi. One possibility is that vesicular-tubular clus-
ters, which are on average 400 nm in diameter [7], may act as
carriers. Recently, it has been shown that procollagen type I is
sorted away from several other proteins early after exit from
the ER suggesting that large molecules may be directed to the
Golgi by a di¡erent mechanism than smaller proteins [8].
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Tra⁄c between the ER and Golgi has been well studied in
both yeast and mammalian systems and many of the compo-
nents involved have been identi¢ed (see [9] and references
therein). In general, the ER-derived vesicles must tether and
dock with the Golgi before fusing with it. Studies in yeast
have identi¢ed a multiprotein complex called transport pro-
tein particle I (TRAPP I) as one of the most upstream factors
required for tethering these vesicles to the Golgi [10]. TRAPP
I is composed of seven polypeptides with no signi¢cant ho-
mology to any protein of known function (Table 1). Besides
tethering the vesicle to the cis side of the Golgi complex,
TRAPP I also facilitates the exchange of nucleotide on a
protein called Ypt1p [11]. By converting Ypt1p to its ‘acti-
vated form’, TRAPP I indirectly allows for the recruitment of
additional factors (e¡ectors of Ypt1p) to the site of the teth-
ered vesicle, setting in motion other poorly de¢ned events
which ultimately allow the vesicle to fuse with the Golgi.
While little functional characterization has been done on
the mammalian TRAPP complex, mammalian cells do possess
orthologues to many of the yeast subunits (Table 1) [12,13]
which are assembled into a high molecular weight complex
[14,15].
3. The ‘missing’ link
Spondyloepiphyseal dysplasia tarda (SEDL) is a skeletal
disorder leading to dysplasia of the large joints. An X-linked
form of this disorder has been described which manifests clin-
ically in a¡ected males as short stature, barrel-chested appear-
ance, dysplasia of the large joints and narrowed intervertebral
disc space [16,17]. The disorder, which presents at V10 years
of age as mild joint pain, often necessitates hip replacement
before the third decade of life [18]. Initial mapping linked the
disease gene to the X chromosome at the Xp22 region [19,20].
Subsequent work showed that the gene, whose protein is
called sedlin, was truncated in three a¡ected males from un-
related lineages [21]. Surprisingly, sedlin is the human ortho-
logue of the TRAPP I subunit Trs20p (see [12]). A more
recent study examined 27 patients clinically diagnosed with
SEDL and a variety of mutations in sedlin were found in
all a¡ected males including frameshifts (resulting in trunca-
tions), mutations predicted to disrupt normal mRNA splicing,
as well as nonsense and missense mutations [18].
Recently, the crystal structure of sedlin was solved [22]. The
structure shows an unusually large number (nearly 15%) of
apolar residues exposed at the surface of the protein, implying
that this subunit is involved in multiple protein^protein inter-
actions. Indeed, several hydrophobic pockets and grooves
have been described on the protein as well as a stretch
(114MNPFY118) of surface-exposed apolar residues. Curiously,
this stretch includes the sequence NPF which has been shown
to be involved in protein^protein interactions with targets
containing the epsin homology (EH) domain [23]. It would
be of interest, therefore, to determine if sedlin in fact interacts
with an EH-domain-containing protein and whether such a
protein plays a role in cartilage development. The crystal
structure also suggests that a missense mutation (D47Y) iden-
ti¢ed in a patient with SEDL, which removes a charge from a
surface-exposed residue, may interfere with a protein^protein
interaction. Thus, the identi¢cation of proteins which interact
with this region of the molecule would be of great interest.
Finally, a structural similarity between sedlin and the regula-
tory domains of the SNAREs ykt6 and sec22b was noted. The
SNAREs are a family of proteins found on donor and accep-
tor membranes which are required for membrane fusion. This
raises the possibility of SNARE^sedlin interactions as well.
Yeast two-hybrid assays have shown that Trs20p and sedlin
interact with chloride intracellular channels [24], c-myc pro-
moter binding protein (MBP)-1 [25] and the yeast proteins
Bet3p [26] and Trs31p [27]. The interaction between Trs20p
and the latter two proteins is not surprising as all these pro-
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with tagged bet3 [15]
Bet5p Yes MUM-2 [39] Yes
Trs20p Yes Sedlin [21] Yes
Bet3p Yes Yes




Fig. 1. The function of the multiprotein complex TRAPP I contain-
ing Trs20p, the yeast orthologue of sedlin, in ER^Golgi tra⁄c is
well established [10]. Sedlin is found in a high molecular weight
complex in HeLa cells as well as in an unassembled state [14], per-
haps allowing it to be involved in multiple processes. Genetic inter-
actions [25] and subcellular localization [28] indicate sedlin may en-
ter the nucleus and might be involved in the regulation of gene
transcription as well. The trs23 subunit, also known as synbindin,
interacts and co-localizes with a cell surface protein involved in
transducing extracellular signals [35] and may be involved in linking
intracellular tra⁄c to extracellular events.
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teins are components of TRAPP I. The interaction of sedlin
with the transcriptional repressor MBP-1 is interesting in light
of the ¢nding suggesting that truncated sedlin accumulates in
or around the nucleus [28]. This latter result suggests that full-
length sedlin may in fact cycle into and out of the nucleus
during its itinerary which would make interaction with nu-
clear proteins a real possibility. Sedlin does not appear to
have the leucine-rich consensus sequence for nuclear export,
found inV35% of proteins which exit the nucleus [29]. How-
ever, in this respect it is interesting to note that three of the
¢nal eight amino acids at the carboxy-terminus of sedlin are
leucines which would be absent in all of the documented
SEDL truncations, thus possibly explaining accumulation of
the truncated form in the nucleus. Alternatively, truncated
sedlin may fail to interact with another protein that would
help shuttle it out of the nucleus. Nevertheless, the interaction
with MBP-1 raises the intriguing possibility of a dual function
for sedlin in both membrane tra⁄c and the regulation of gene
expression (Fig. 1), perhaps helping to explain the patholog-
ical basis for SEDL. It would be of interest to determine
whether sedlin interacts with other, perhaps chondrocyte-spe-
ci¢c, transcriptional repressors (see below).
4. Future perspectives
Although a tra⁄cking defect may be the more favored ex-
planation for the etiology of SEDL (see below), several inter-
esting cell biological questions regarding membrane tra⁄c and
cartilage development arise. First, if sedlin is ubiquitously ex-
pressed [21,30], why does mutation of the protein lead to a
tissue-speci¢c disorder? To address this question, it will be of
interest to assess ER^Golgi tra⁄c in SEDL patients. In par-
ticular, the tra⁄cking of the proteins destined for the cartilage
should be examined. One possibility is that sedlin is intimately
involved in recognizing a particular class of ER-derived trans-
port vesicles enriched in these proteins. Recall that the ‘stan-
dard’ ER-derived vesicle is V50 nm in diameter while some
of the cartilage proteins are too large to ¢t into such vesicles.
Whether there is a second class of ER-derived vesicles in
chondrocytes is mere speculation. It should be noted, how-
ever, that since two classes of vesicles have been reported to
bud from the ER in the lower eukaryotic organism Saccha-
romyces cerevisiae [31] it is not unreasonable to speculate that
higher eukaryotes may have evolved alternative transport
mechanisms from the ER which may vary from cell to cell.
Interestingly, an early sorting event after ER exit has been
noted in mammalian cells resulting in the segregation of pro-
collagen type I from the vesicular stomatitis virus G protein
and ERGIC53 [8]. It is tempting to speculate that sedlin might
be directly involved in recognition of these procollagen-con-
taining transport intermediates (see [32]). Indeed, the extracel-
lular matrix from one SEDL patient was reported to contain
collagen ¢brils that were shorter than normal and frayed as
well as ¢brils of varying diameter [32], suggestive of a defect in
the normal secretion of this macromolecule in this patient. A
comparison between the secretion of collagen and that of
other smaller proteins from this patient would be of interest.
Another possibility for the tissue-speci¢c defect in SEDL
patients could lie in the TRAPP subunit composition. The
arrangement of the subunits within the complex could vary
between tissues, with sedlin being more heavily represented in
the complex in chondrocytes. A similar situation is found in
yeast where, in this case, altering the TRAPP I subunit com-
position changes the activity of the complex (now referred to
as TRAPP II) [10]. Generation of highly speci¢c antibodies to
each of the subunits will help to address this possibility.
Second, why is SEDL a late onset disorder and not man-
ifested during initial formation of the embryonic cartilaginous
network, a precursor to certain skeletal elements? A possible
explanation for this question lies in the numerous pseudo-
genes for sedlin in the genome. One in particular (a retropseu-
dogene on chromosome 19) is transcribed [21,25,28]. The
pseudogene is predicted to encode a full-length protein iden-
tical to that found on the X chromosome. However, it has yet
to be demonstrated whether the mRNA is translated in vivo.
If so, one might speculate that this retropseudogene provides
redundancy early in development and that transcription and/
or translation of this retropseudogene is turned o¡ later in
development, leaving the sole expressed copy of sedlin origi-
nating from the X chromosome. If truncated sedlin fails to
interact with MBP-1 then, in SEDL patients, this might lead
to the clinical manifestations described above. In this respect
it is noteworthy that carrier females appear to be asymptom-
atic (see [18]) indicating that only one copy of the wild-type
protein is su⁄cient for sedlin function. This result would also
provide the precedent for future studies aimed at examining
the developmental regulation of membrane tra⁄cking factors.
Third, is the interaction between sedlin and MBP-1 of phys-
iological signi¢cance? It is not unreasonable to speculate that
chondrocytes contain tissue-speci¢c transcriptional regulators,
given that both osteoblasts and chondroblasts possess tran-
scription factors such as Osf2/Cbfa1 [33] and Sox9 [34], each
playing a key role in tissue-speci¢c growth. If sedlin interacts
with chondrocyte-speci¢c factors involved in transcription,
then the exciting possibility exists that sedlin might be in-
volved in both membrane tra⁄c and gene expression (Fig.
1). This would not be the ¢rst TRAPP subunit purported to
function outside of the complex. Another TRAPP subunit
(trs23), designated synbindin [35], was shown to bind to cell
surface heparin sulfate proteoglycans of the syndecan family
and is reportedly involved in neuronal dendritic spine forma-
tion. Interestingly, syndecan-2 plays a role in osteoblast signal
transduction [36] and is expressed during bone development
and osteoblast di¡erentiation [37] while syndecan-3 is believed
to transduce signals in chondrocyte development [38]. In light
of these ¢ndings, a more general question could be asked: do
TRAPP subunits function outside the complex to somehow
link other cellular events to membrane tra⁄c (Fig. 1)? This is
indeed an intriguing possibility which requires further exami-
nation. Perhaps, then, it is noteworthy that preliminary evi-
dence indicates sedlin is a phosphoprotein (unpublished ob-
servation). Determination of the physiological function of the
phosphorylation site(s) may help begin to unravel the answer
to this question.
5. Conclusion
Although a defect in membrane tra⁄c may be the most
straightforward explanation for the disease state, tying togeth-
er recent literature indicates other factors may come into play.
The growing literature suggests that sedlin function (and per-
haps that of other TRAPP subunits) may not be restricted to
membrane tra⁄c. The intersection where sedlin now stands
indicates other areas of research such as signal transduction
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and, perhaps, gene expression may yet become involved. To
examine the multifunctional role of sedlin, it will be necessary
to combine a variety of tools available to the developmental
cell biologist, such as electron microscopy, knockout and
transgenic mouse models, and RNA interference, with studies
of subunit composition/assembly, protein^protein interactions
and standard assays of membrane tra⁄c. In this way, we will
gain a better understanding of the link between cartilage de-
velopment and protein secretion in disease and health.
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